You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 9,592,272

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,592,272

Title:	Treatment of osteoarthritis with incretin hormones or analogues thereof
Abstract:	The present invention relates to the use of the incretin hormones glucagon-like peptide-1 or GLP-1 and glucose-dependent insulinotropic polypeptide or GIP, or of analogs thereof, in particular the analogs resistant to dipeptidyl peptidase IV, in the treatment of osteoarthritis, in particular for inhibiting or slowing down cartilage destruction.
Inventor(s):	Berenbaum; Francis (Gif sur Yvette, FR), Bougault; Carole (Lyons, FR), Attali; Claire (Antony, FR)
Assignee:	UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR)
Application Number:	14/424,475
Patent Claims:	1. A method of treating osteoarthritis comprising administering intra-articularly a therapeutically effective dose of a peptide selected from the group consisting of a glucagon-like peptide 1 (GLP-1), a gastric inhibitory peptide (GIP) and analogues thereof resistant to dipeptidyl peptidase IV (DPP-IV) to a subject having osteoarthritis, wherein the therapeutically effective dose of the peptide or the analogue thereof inhibits or slows down the arthritic cartilage destruction. 2. The method according to claim 1, wherein the peptide comprises a sequence selected from the group consisting of SEQ ID NOs: 1 to 6. 3. The method according to claim 2, wherein the peptide is selected from the group consisting of the SEQ ID NO: 4 and SEQ ID NO: 3. 4. The method according to claim 2, wherein the peptide is SEQ ID NO: 6. 5. The method according to claim 1, wherein the peptide is an analogue of the GLP-1 or GIP and is resistant to DPP-IV. 6. The method according to claim 1, wherein the peptide is an analogue of the GLP-1 and is resistant to DPP-IV. 7. The method according to claim 6, wherein the peptide is selected from the group consisting of exenatide, liraglutide, exendin-4, albiglutide, taspoglutide, lixisenatide, dulaglutide (LY2189265), LY315902, LY2199265, LY2428757, semaglutide (NN9535), CJC-1131, CJC-1134 and ZP10. 8. The method according to claim 7, wherein the peptide is selected from the group consisting of exenatide and liraglutide. 9. The method according to claim 1, said method comprising the administration of the peptide selected from the group consisting of the GLP-1, the GIP and the analogues thereof resistant to dipeptidyl peptidase IV (DPP-IV) in combination with one or more other active substances selected from the group consisting of analgesics, non-steroidal anti-inflammatories, steroidal anti-inflammatories and slow-acting anti-arthritic agents. 10. The method according to claim 9, wherein the peptide and said other active substance(s) are administered simultaneously. 11. The method according to claim 9, wherein the peptide and said other active substance(s) are administered sequentially. 12. The method according to claim 1, wherein the peptide is administered in combination with local treatments for osteoarthritis. 13. The method according to claim 1, wherein said method comprises the intra-articular administration of a pharmaceutical composition comprising one or more peptides selected from the group consisting of the GLP-1, the GIP and the analogues thereof resistant to dipeptidyl peptidase IV (DPP-IV) and a pharmaceutically acceptable support and/or excipient. 14. The method according to claim 13, wherein said pharmaceutical composition comprises one or more other active substances selected from the group consisting of analgesics, non-steroidal anti-inflammatories, steroidal anti-inflammatories and slow-acting anti-arthritic agents.

Details for Patent 9,592,272

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	04/15/2014	⤷ Try a Trial	2032-08-30
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	09/18/2014	⤷ Try a Trial	2032-08-30
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	09/04/2020	⤷ Try a Trial	2032-08-30
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471	07/27/2016	⤷ Try a Trial	2032-08-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.